Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies

1Division of Gastroenterology, Department of Medicine, University of California, San Francisco 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco 3Division of Transplant Surgery, Department of Surgery, University of California, San Francisco Disclosures: Neil Mehta consults for, advises, and received institutional grants from FujiFilm WAKO and Genentech/Roche. He consults for and advises Exact Sciences, Merck, and Exelixis. He received institutional grants from Glycotest and Target Pharmasolutions. Robin K. Kelley consults for, advises, and received institutional grants from Genentech/Roche. She consults for and advises Compass, Exact Sciences, Gilead, Kinnate, and Tyra Therapeutics. She advises and received institutional grants from AstraZeneca, Exelixis, and Merck. She received institutional grants from Aigos, Bayer, BMS, Eli Lily, EMD Serono, Loxo Oncology, Novartis, Partiner Therapeutics, QED, Relay Therapeutics, Surface Oncology, and Taiho. R Katie Kelley and Francis Y. Yao: Indicates co-senior authors Correspondence Neil Mehta, MD, University of California, San Francisco, 513 Parnassus Avenue, Room S-357, San Francisco, CA 94143-0538. Email: [email protected]